La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lixte Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lixte Biotechnology..

Lixte Biotechnology (NASDAQ:LIXT) Azioni, Catena delle Opzioni

Lixte Biotech Hldgs

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. - Warrants

Press Releases

New Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active Form

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

News

General

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

LIXT

LIXTW

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

180 Life Sciences

BioCardia

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Equillium

HOOKIPA Pharma

iBio

Lixte Biotechnology

Leap Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Pelthos Therapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Windtree Therapeutics, Inc. - Common Stock

Comments

Lixte Biotechnology

Lixte Biotechnology (LIXT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO